Blog - Andromeda

Read our Blogs

Immunotherapy in Breast Cancer: The New Era of Hope Immunotherapy in Cancer Treatment: A New Era of Hope Understanding its role in Breast Cancer at Different Stages: Cancer treatment has evolved dramatically over the past decade. Among the most promising advancements is immunotherapy a treatment that uses the bodys own immune system to recognize and destroy cancer cells. Normally, our immune system is highly skilled at identifying anything that does not belong in the body. However, cancer cells can cleverly hide and suppress the immune response. Immunotherapy helps the immune system wake up, find cancer cells, and attack them more effectively. This approach is different from chemotherapy or targeted therapy, which directly act on cancer cells. Instead, immunotherapy gives power back to the bodys natural defense system. Immunotherapy drugs work by re-activating the immune systems ability to recognize and eliminate cancer cells. Tumors often evade immune destruction by exploiting regulatory pathways such as immune checkpoints for example, PD-1/PD-L1 and CTLA-4 which normally function to prevent excessive immune activation. Checkpoint inhibitor immunotherapies are monoclonal antibodies that block these inhibitory receptors or ligands, thereby releasing the brakes on cytotoxic T cells and allowing them to attack malignant cells more efficiently. Other forms of immunotherapy include CAR-T cell therapy, in which a patients T cells are genetically engineered to express specific receptors targeting tumor antigens, and cancer vaccines, which stimulate adaptive immune memory against tumor-associated markers. Additionally, cytokine-based treatments and immune stimulators enhance immune cell proliferation and activity within the tumor microenvironment. Together, these strategies aim to overcome tumor-induced immune suppression, achieve durable antitumor responses, and establish long-term immunologic surveillance to prevent relapse. How Does Immunotherapy Work? Immunotherapy works in several ways, such as: Checkpoint inhibitors: Cancer cells often use brakes on the immune system to avoid attack. These drugs release those brakes so immune cells can act freely. Immunomodulators: They boost the overall activity of the immune system. Cell-based therapies: Immune cells are enhanced or engineered outside the body and then infused back to target cancer more strongly. Cancer vaccines: These help the body recognize cancer-specific markers and develop long-term defense. These treatments have already improved outcomes in melanoma, lung cancer, kidney cancer, and many others. Immunotherapy in Breast Cancer: Breast cancer is a very diverse disease, with different biological subtypes. Immunotherapy is becoming particularly valuable in Triple-Negative Breast Cancer (TNBC) a type that lacks hormone receptors and HER2 expression and tends to be more aggressive. Heres how immunotherapy fits into different stages of breast cancer: 1. Early-Stage Breast Cancer For patients with high-risk early-stage TNBC, immunotherapy is now used in combination with chemotherapy before surgery. This approach increases the chance of completely eliminating cancer in the breast and lymph nodes. It may also reduce risk of recurrence in the future. 2. Locally Advanced Breast Cancer When the tumor is large or has spread to nearby nodes, but not distant organs, immunotherapy plus chemotherapy can shrink the cancer. This helps make surgery more successful and improves long-term outcomes. 3. Metastatic / Stage IV Breast Cancer Immunotherapy has shown meaningful benefit in patients whose TNBC expresses PD-L1, an immune-checkpoint marker. It can help control cancer for longer, maintain better quality of life, and may extend survival. In some selected patients, tumors shrink significantly, making ongoing treatment more manageable. Why Immunotherapy Matters More personalized treatment based on cancer biology Better tolerance for many patients compared to traditional chemotherapy Long-lasting immune memory, which can help keep cancer away even after treatment stops It represents a major shiftfrom only attacking cancer to empowering the immune system to stay vigilant. Side Effects of Immunotherapy in Breast Cancer Patients Immunotherapy generally has a different side-effect profile compared to chemotherapy. Because it activates the immune system, the most common reactions come from the immune system attacking healthy tissues these are called immune-related adverse events (irAEs). Some commonly seen side effects include: Skin reactions Rash, itching, dryness, or changes in skin color. These are usually mild and manageable with creams or medicines. Fatigue A common effect that can vary from mild tiredness to more significant weakness. Gastrointestinal symptoms Diarrhea or inflammation of the bowel (colitis) can occur in some patients. Hormone gland inflammation the thyroid, adrenal glands, or pituitary gland can get affected, leading to hormonal imbalance. Symptoms may include weight changes, hair loss, mood changes, or low energy, often requiring hormone replacement. Lung inflammation (pneumonitis) Causes cough, breathlessness, or chest discomfort. This needs prompt medical attention. Liver inflammation (hepatitis) Usually detected by blood tests before symptoms appear. While many side effects are mild, some can be serious if not addressed early. The good news is that most irAEs respond very well to timely treatment, especially with corticosteroids or temporary pause of immunotherapy. Why monitoring matters: During immunotherapy, patients are closely followed with regular check-ups and blood tests. Any new symptom even if small should be reported early so that doctors can act quickly and prevent complications. With proper monitoring, most patients continue treatment safely and benefit from its long-term effects. Common Immunotherapy Drugs Used in Breast Cancer At present, immunotherapy in breast cancer is mainly focused on Triple-Negative Breast Cancer (TNBC). The most commonly used drug is Pembrolizumab, a checkpoint inhibitor that targets the PD-1 receptor on immune cells. By blocking this receptor, the medicine allows T-cells to recognize and attack cancer cells more effectively. Pembrolizumab is now approved for use in early-stage high-risk TNBC along with chemotherapy before surgery, as well as in metastatic TNBC where the tumor expresses the PD-L1 marker. Another drug used in selected metastatic TNBC cases is Atezolizumab, which targets the PD-L1 protein on cancer cells and immune cells. These medicines have shown meaningful benefits in controlling disease and improving long-term outcomes in eligible patients. The Road Ahead: Research is rapidly progressing to: Expand immunotherapy beyond TNBC to other breast cancer subtypes Identify which patients benefit the most Improve combinations with targeted therapy, hormone therapy, and radiation Immunotherapy is not yet for all breast cancer patients, but it is a strong and growing pillar of modern cancer care. Landmark Trials in Immunotherapy for Breast Cancer Landmark trials related to the immunotherapy in breast cancer: The introduction of immunotherapy in breast cancer has been driven by major clinical trials, particularly in triple-negative breast cancer (TNBC). The KEYNOTE-522 trial was a breakthrough in early-stage disease, showing that adding pembrolizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response and improved event-free survival, leading to global approval for high-risk early TNBC. In metastatic settings, KEYNOTE-355 demonstrated that pembrolizumab combined with chemotherapy offered a meaningful survival benefit in PD-L1 positive metastatic TNBC, establishing it as a standard first-line option. Another key trial, IMpassion130, evaluated atezolizumab with nab-paclitaxel in metastatic TNBC and showed improved progression-free survival in PD-L1 positive patients, marking the first immunotherapy approval in advanced breast cancer. Although later trials such as IMpassion131 did not replicate the same benefit, the collective evidence from these pivotal studies has opened a new and hopeful chapter, integrating immunotherapy as an important treatment pillar in selected breast cancer patients. Final Takeaway: These drugs are not for all breast cancers they benefit patients whose tumors show PD-L1 expression and are mostly used in TNBC. They are often combined with chemotherapy for better effectiveness. Selection of patients is done using specialized biomarker testing. Immunotherapy has opened a new chapter in breast cancer treatment one filled with innovation, hope, and better outcomes. As research continues, more patients will have access to this powerful and personalized strategy to fight cancer. #breastcancer #TNBC #immunotherapyforbreastcancer #breastcancersurvival

Breast Cancer Surgery Without Losing The Breast A century of change in a single operation In the early 1900s, Halsteds radical mastectomyremoving the entire breast, pectoral muscles, and extensive nodeswas the unquestioned standard for operable breast cancer. As systemic therapies emerged and our understanding of tumour biology matured, it became clear that more surgery wasnt always better. Modified radical mastectomy (MRM) preserved the pectoral muscles, reduced morbidity, and laid the foundation for the next leap: breast conservation surgery (BCS)tumour-focused excision with clear margins, combined with radiotherapy. The central insight was profound: survival depends as much on biology and systemic control as on extent of local surgery. Randomized trials across decades have since confirmed that appropriately selected patients can keep their breast without compromising survival. From Mastectomy to BCS: What the Randomized Trials Proved Two landmark randomized trials anchor the BCS evidence base. The NSABP B-06 study demonstrated, at 20-year follow-up, no difference in overall survival among total mastectomy, lumpectomy alone, and lumpectomy plus radiotherapy; radiotherapy, however, significantly reduced local recurrence after lumpectomy. Similarly, the Milan (Veronesi) quadrantectomy trial reported equivalent long-term survival between BCS and radical mastectomy, establishing oncologic safety for conservation. These data changed global practice and underwrite todays guidelines The EBCTCG Meta-analysis: Why Radiotherapy Matters After BCS The Early Breast Cancer Trialists Collaborative Group (EBCTCG) pooled individual patient data from 17 trials (10,801 women) and provided the most influential quantification of radiotherapys value after BCS: radiation halved the 10-year risk of any first recurrence (35.0% 19.3%) and reduced 15-year breast cancer mortality by about one-sixth. These proportional benefits were broadly similar across subgroups, though absolute benefit varied with baseline risk. This single overview codified the principle that BCS must be paired with high-quality radiotherapy for durable local control and survival benefit. De-escalation Done Right The shift from radical mastectomy to MRM to BCS is part of a larger oncology movement: de-escalation with precision. We aim to minimize treatment burden without sacrificing curesmaller operations, focused radiotherapy, omission of axillary dissection in node-negative or carefully selected post-neoadjuvant settings, and tailored systemic therapy. EBCTCG overviews across eras consistently show that better local control translates to fewer deaths, but beyond a certain point, more tissue removal does not improve survival. The art is matching treatment intensity to disease biology and patient values. BCS vs Mastectomy: The Modern Data (And Why BCS Often Wins) While RCTs established equivalence in survival between BCS+RT and mastectomy, large contemporary population studies (reflecting advances in systemic therapy, imaging, pathology, and radiotherapy) frequently show a survival advantage for BCS+RT over mastectomy in early breast cancer. For example, a nationwide Dutch analysis showed improved 10-year overall and relative survival with BCS+RT compared with mastectomy (with caveats about residual confounding). More recently, a 2024 meta-analysis again suggested a survival advantage for BCS+RT in early disease. These findings should be presented carefully to patientsas observational data subject to selection effectsbut they reinforce that BCS is not a compromise; it is often the best option for eligible patients. BCS After Neoadjuvant Chemotherapy: Expanding Eligibility Neoadjuvant systemic therapy (NST) downstages tumours, increasing the proportion of women eligible for conservationespecially in HER2-positive and triple-negative subtypes that can achieve pathologic complete response. Meta-analyses focusing on BCS after NST show comparable survival to mastectomy and acceptable local control when margins are clear and radiotherapy is optimized, though some reports note higher positive-margin rates and emphasize meticulous imaging, clip placement, and pathologic handling. The message: in experienced multidisciplinary programs, BCS after NST is both feasible and safe for many, provided we adhere to rigorous selection and technique. Indias Journey: Acceptance, Access, and Oncoplastic Momentum In India, uptake of breast conservation surgery historically lagged behind Western rates due to later stage at presentation, limited access to radiotherapy, variable training, and socio-cultural preferences. Earlier reports documented conservation rates between 11% and 34%. Yet over the last decade, comprehensive cancer centres (e.g., Tata Memorial Hospital, Mumbai) have documented steady increases in BCS utilization as awareness, imaging, pathology, radiotherapy capacity, and surgical expertise improved. Surveys of Indian surgeons show that specialized onco-surgical training and reliable access to radiotherapy independently drive greater BCS offering. The trajectory is positiveand oncoplastic integration is accelerating acceptance by delivering better shape and symmetry without compromising margins. The Rise of Oncoplastic Breast Surgery Oncoplastic techniques merge oncologic resection with plastic surgical principles to maintain or improve cosmesis while ensuring negative margins. Level I approaches (rearrangements within the breast) and Level II techniques (therapeutic mammoplasty, volume replacement) allow larger tumours relative to breast size to be safely treated with conservation. The clinical impact is twofold: more women become candidates for BCS, and fewer require re-excision for close margins when planning anticipates tissue movement and clips mark the cavity for precise radiotherapy boosts. Indian experts outline pragmatic pathways for building oncoplastic programseven in resource-constrained settingsthrough training, patient education, and team-based care. What Patients Feel and Report: PROMs After BCS In an era of shared decision-making, patient-reported outcome measures (PROMs) are as essential as survival curves. Tools like BREAST-Q and EORTC QLQ-BR23 capture satisfaction with breasts, psychosocial and sexual well-being, and treatment side-effects over time. Multiple comparative studies show that women treated with BCS plus radiotherapy often report equal or higher long-term satisfaction and better psychosocial/sexual well-being than those undergoing mastectomy (with or without reconstruction). Importantly, contemporary data suggest that at 10 years, satisfaction with breasts can be similar between BCS+RT and mastectomy + reconstruction, but psychosocial/sexual domains tend to favour BCS. For hospital teams, routinely embedding PROMs in follow-up is a practical way to individualize counseling and continuously improve technique. <div class="ivm-view-attr__img-wrapper "> Practical Take-Home for Clinicians and Patients BCS is oncologically safe for the majority of women with early breast cancer when combined with radiotherapy, with randomized trials confirming equivalent survival to mastectomy and superior local control versus lumpectomy alone. Modern datasets frequently show better survival with BCS+RT than mastectomylikely reflecting advances in imaging, radiotherapy, systemic therapy, and careful selectionreinforcing BCS as a first-choice for eligible patients. After neoadjuvant therapy, BCS is feasible and safe in many; meticulous clip placement, margin assessment, and tailored radiotherapy are non-negotiable. Oncoplastic surgery expands conservation to more women while enhancing cosmetic outcomescritical for long-term quality of life and confidence. In India, acceptance is rising as radiotherapy access improves and specialist training spreads. Education, pathway standardization, and PROMs should be routine. Our Commitment At Andromeda Cancer Hospital, breast conservation is not just a surgical techniqueits a philosophy of care. Every woman is evaluated in a multidisciplinary tumour board; we place markers at biopsy, use pre- and post-neoadjuvant imaging to define the target precisely, perform oncoplastic resections tailored to body habitus and tumour location, and coordinate with radiation oncology for accurate boosts to the tumour bed. We also try to integrate PROMs into follow-up, because how our patients feelabout their body, relationships, and daily lifematters as much as what their scans show. When conservation is safe, we advocate for it. When mastectomy is necessary or preferred, we ensure access to immediate or delayed reconstruction and survivorship support. For many women, keeping the breast and curing the cancer go hand-in-hand. If youor someone you lovehas been diagnosed with breast cancer, ask your care team whether breast conservation is right for you. Evidence-based, oncoplastic, patient-centered breast surgery is availableand it changes lives.

Bone Health in Breast Cancer Survivors: Often Neglected Part of Survivorship Care Modern Breast Cancer Management Care Beyond the CancerHolistic Care for Life Breast cancer is the commonest cancer affecting women globally as well as in India. Last few decades have seen significant advancements in the understanding and the diagnostic and treatment options for breast cancer. As a result, the outcome of the disease is improving day by day. As a result of improvement in the survival outcome, the quality-of-life concerns of the breast cancer survivors have come in the sharp focus. Long term bone health is one crucial aspect of long-term wellbeing of the breast cancer survivors, sadly this often goes unnoticed. For many women, especially those undergoing hormonal therapies or chemotherapy-induced menopause, bone loss is a silent companion to their cancer journey. Protecting bone strength is, therefore, not merely about preventing fracturesits about preserving quality of life, independence, and confidence in survivorship. Why Bone Health Matters in Breast Cancer Bone is a living tissue, continuously renewed through a balance between bone formation and bone resorption. Several factors in breast cancer disturb this balance: Natural aging and menopause reduce estrogen levels, leading to accelerated bone loss. Cancer therapiesespecially those that reduce estrogen or ovarian functionfurther intensify this process. Metastatic disease may directly involve the bone, causing pain and structural weakness. Thus, the risk of osteopenia, osteoporosis, and fractures is significantly higher in breast cancer survivors compared to women of similar age without cancer. Causes and Risk Factors for Bone Loss Bone health in breast cancer patients is influenced by a mix of disease-related, treatment-related, and lifestyle-related factors. 1. Treatment-Induced Factors Aromatase Inhibitors (AIs): Drugs like letrozole, anastrozole, and exemestane suppress estrogen production, leading to a 23% loss in bone density each year in postmenopausal women. Chemotherapy-Induced Ovarian Failure: Premenopausal women receiving chemotherapy may experience premature menopause, drastically reducing estrogen levels. Ovarian Suppression / Ablation: Medical (GnRH analogues) or surgical ovarian suppression also accelerates bone loss. Corticosteroids: Used intermittently in chemotherapy or antiemetic regimens, they can impair bone formation. Radiation Therapy: Radiation to the chest wall or spine can affect local bone integrity, especially in the ribs or vertebrae. 2. Disease-Related Factors Bone Metastases: Common in advanced breast cancer, causing pain, pathological fractures, hypercalcemia, and reduced mobility. Cytokine-mediated Bone Resorption: Tumour-secreted factors (e.g., RANKL, IL-6) promote osteoclast activation. 3. Lifestyle Nutritional Factors Sedentary lifestyle, reduced physical activity during and after completion of the treatment Low calcium and vitamin D intake Smoking and alcohol consumption Low body weight and malnutrition Impact of Breast Cancer Treatment on Bone Health Breast cancer treatments save livesbut they often come at the cost of accelerated skeletal aging. AIs vs. Tamoxifen: While aromatase inhibitors cause bone loss, tamoxifen actually preserves or increases bone density in postmenopausal women (though it can reduce it in premenopausal women). Chemotherapy: In younger women, chemotherapy-induced menopause can cause bone density loss equivalent to 10 years of natural aging within just 612 months. Endocrine Therapy Duration: With adjuvant endocrine therapy now extending up to 10 years in some cases, the long-term skeletal effects are substantial. Unmanaged bone loss can lead to osteoporotic fractureswhich not only impair mobility but also reduce survival and independence. Having such fractures is not only physically debilitating, it also leads to loss of mobility, dependence on others, nervousness, loss of confidence in performing day to day self-care activities and eventually depression. Diagnosis and Assessment Early identification of bone loss is crucial. Guidelines recommend a baseline bone mineral density (BMD) assessment before starting aromatase inhibitors or ovarian suppression therapy. 1. Bone Mineral Density (DEXA Scan): Gold standard for diagnosing osteopenia and osteoporosis. T-score 1.0 = Normal T-score between 1.0 and 2.5 = Osteopenia T-score 2.5 = Osteoporosis 2. Laboratory Tests: Serum calcium, phosphate, alkaline phosphatase 25-hydroxy vitamin D Renal and thyroid function (to rule out secondary causes) 3. Bone Turnover Markers (Optional): Used in research or specialized settings to monitor therapy response. 4. Imaging for Metastases: If bone pain or high ALP levels are present, bone scan, PET-CT, or MRI should be done to detect metastases early. Prevention and Lifestyle Precautions Bone health preservation begins from the start of cancer therapy. The following preventive steps can make a substantial difference: 1. Nutrition Calcium: 10001200 mg/day (preferably from dietmilk, curd, paneer, ragi, almonds). Vitamin D: 8001000 IU/day; exposure to sunlight for 1520 minutes daily. Protein: Adequate intake supports bone matrix maintenance. 2. Exercise Weight-bearing exercises (brisk walking, stair climbing, dancing) and resistance training improve bone strength and balance. Avoid high-impact activities if bone metastases or fractures are present. 3. Lifestyle Modifications Stop smoking and reduce alcohol. Maintain a healthy BMI. Prevent fallsgood lighting, supportive footwear, and home safety measures, bed railings, anti-skid floor in the bathrooms and other living areas. Medical Management For women at significant risk of bone loss (T-score 2.0, or 1.5 with additional risk factors), pharmacologic intervention is recommended alongside lifestyle measures. 1. Bisphosphonates Examples: Zoledronic acid (IV yearly or 6-monthly), Alendronate, Risedronate. Benefits: Prevent osteoporosis, reduce skeletal events, and may lower bone metastasis risk in postmenopausal women. 2. Denosumab A monoclonal antibody against RANKL (60 mg subcutaneous every 6 months). Effective alternative to bisphosphonates; improves bone density and reduces fractures. 3. Hormone Replacement Therapy (HRT) Routinely not used in breast cancer patients due to potential recurrence risk. 4. Analgesics and Supportive Care For metastatic bone disease: pain management, radiation therapy, and Orthopaedic interventions as needed. Follow-up and Monitoring Long-term follow-up is key to maintaining skeletal integrity and preventing late complications. DEXA scan: Every 12 years to monitor bone density trends. Vitamin D and calcium levels: Check annually. Treatment adherence: Ensure bisphosphonate or denosumab schedules are followed. Dental evaluation: Before starting bisphosphonates or denosumab, to prevent osteonecrosis of the jaw. Symptom review: Ask about back pain, height loss, or new pain sites during follow-up visits. Special Considerations Premenopausal women: Monitor for chemotherapy-induced menopause and initiate early bone protection if required. Metastatic disease: Bisphosphonates or denosumab are mandatory to prevent skeletal-related events. Elderly patients: Focus on fall prevention and functional independence. <div class="ivm-view-attr__img-wrapper "> Conclusion: Building Strength from Within Bone health is a vital yet often overlooked aspect of breast cancer care. By integrating routine screening, preventive nutrition, exercise, and timely medical interventions, we can protect the skeletal foundation that supports every woman through and beyond her cancer journey. The message is simple yet powerful We treat the cancer, but we also care for the woman who undertakes that treatment journey. As we celebrate survivorship, lets ensure that every breast cancer warrior stands strongnot just cancer-free, but bone-healthy and life-ready.

Young Women with Breast Cancer: Preserving Fertility, Preserving Hope Young Women with Breast Cancer: Preserving Fertility, Preserving Hope Breast cancer is increasingly being diagnosed in younger women a group for whom life goals often extend beyond cancer survival to dreams of motherhood, career, and personal fulfilment. The diagnosis, while daunting, no longer needs to mean the end of these dreams. Advances in oncology and reproductive medicine now make it possible for many young women to preserve their fertility and even achieve pregnancy after successful treatment. This article explores key aspects of fertility preservation, the role of GnRH analogues, data supporting their use, and the concept of planned interruption or tamoxifen holiday for women on long-term hormonal therapy who wish to conceive. Breast Cancer in Young Women: A Unique Challenge Approximately 510% of breast cancers occur in women under 40, and this number is rising in several countries, including India. These women face unique biological, emotional, and social challenges. Cancers in younger women tend to be biologically more aggressive, often hormone receptor-positive, and require systemic treatments like chemotherapy and hormonal therapy that can impact ovarian function. For these women, discussions around fertility are not a luxury they are an essential part of comprehensive cancer care. Preserving fertility is not merely about having children; it is about preserving choices, hope, and a sense of normalcy in life after cancer. Impact of Cancer Treatment on Fertility Chemotherapy-induced ovarian toxicity is the major concern. Alkylating agents like cyclophosphamide can cause irreversible damage to ovarian follicles, leading to premature ovarian insufficiency. The degree of risk depends on: Age at treatment (younger women have a higher ovarian reserve) Type and dose of chemotherapy Duration of therapy Use of concurrent gonadotoxic agents Hormonal therapy, especially tamoxifen (commonly prescribed for 510 years in hormone receptor-positive cancers), delays childbearing further, increasing the chance of age-related infertility. Thus, early fertility counselling ideally before starting systemic therapy is critical. Oncologists, reproductive specialists, and patients should work together to discuss and plan available fertility preservation options. Fertility Preservation Options Fertility preservation can broadly be classified into established and experimental methods. The choice depends on time available before starting chemotherapy, patients age, and personal circumstances. 1. Embryo Cryopreservation This is the most established and successful method. It involves ovarian stimulation, egg retrieval, and fertilization with partners or donor sperm before freezing embryos. Modern vitrification techniques ensure excellent survival rates and outcomes comparable to natural conception. 2. Oocyte Cryopreservation (Egg Freezing) For unmarried women or those without a partner, oocyte cryopreservation is the preferred option. Recent improvements in freezing techniques have made this an equally effective approach, with live birth rates approaching those from fresh eggs. 3. Ovarian Tissue Cryopreservation A promising technique, especially when chemotherapy must begin immediately or in prepubertal girls. A part of ovarian cortex containing primordial follicles is surgically removed, frozen, and later reimplanted. While still considered somewhat experimental, over 200 live births worldwide have been reported with this method. 4. Ovarian Suppression with GnRH Analogues The simplest and least invasive option and one that can be implemented immediately is the use of GnRH analogues (gonadotropin-releasing hormone agonists) during chemotherapy. Role of GnRH Analogues in Fertility Preservation GnRH analogues (like goserelin or leuprolide) act by temporarily suppressing ovarian function, placing ovaries in a resting state during chemotherapy. The hypothesis is that dormant follicles are less susceptible to cytotoxic damage. Clinical Evidence For years, the role of GnRH analogues was debated, but high-quality randomized trials and meta-analyses have now clarified their benefit. The landmark POEMS/S0230 trial, published in the New England Journal of Medicine (2015), provided strong evidence. In this study involving premenopausal women with hormone receptor-negative breast cancer, those who received goserelin along with chemotherapy had: 70% lower rate of premature ovarian failure Double the rate of post-treatment pregnancies compared to those who did not receive goserelin No compromise in disease-free or overall survival Subsequent meta-analyses have confirmed these findings, showing that GnRH analogues significantly reduce the risk of chemotherapy-induced ovarian failure, irrespective of hormone receptor status. Thus, current ASCO and ESMO guidelines recommend the use of GnRH analogues during chemotherapy for ovarian function preservation in young premenopausal women who are receiving gonadotoxic chemotherapy especially when other fertility preservation methods are not feasible or as an adjunct to them. Conceiving Naturally After Treatment Completion One of the most frequent questions asked by young survivors is: Can I conceive naturally after breast cancer treatment? The reassuring answer is yes; many can. Studies suggest that up to 5060% of women who resume menses after chemotherapy are capable of natural conception, depending on their age, baseline ovarian reserve, and type of treatment received. Importantly, pregnancy after breast cancer does not increase the risk of recurrence even in hormone receptor-positive disease provided an appropriate disease-free interval is observed before attempting conception. Tamoxifen and the Pregnancy Pause The POSITIVE Trial For women with hormone receptor-positive breast cancer, tamoxifen or aromatase inhibitors are prescribed for 510 years as adjuvant endocrine therapy. This prolonged course can delay pregnancy until a womans mid or late 30s a critical issue for fertility. The recently published POSITIVE (IBCSG 48-14) trial, presented at San Antonio Breast Cancer Symposium 2022 and later published in NEJM 2023, addressed this question directly. The study enrolled over 500 young women who wished to become pregnant but were on adjuvant endocrine therapy. Participants paused their therapy for up to two years to allow conception and childbirth, after completing at least 18 months of treatment. Key results were encouraging: 74% achieved pregnancy, and 64% had at least one live birth. After a median follow-up of 3 years, no increase in cancer recurrence was observed compared to matched controls continuing endocrine therapy. The findings affirm that planned interruption of endocrine therapy (tamoxifen holiday) can be safely considered under close medical supervision for selected women desiring pregnancy. After childbirth and breastfeeding, endocrine therapy can be resumed to complete the planned duration. A Multidisciplinary Path Forward Fertility preservation is a rapidly evolving field that demands seamless coordination between oncology, reproductive medicine, and psychosocial support teams. Key steps for best outcomes include: Early referral to a fertility specialist, ideally before starting systemic therapy Discussion of all available options, including GnRH analogues during chemotherapy Individualized counselling about timing and safety of pregnancy Emotional and psychological support through survivorship Oncologists must normalize these discussions. For a young woman, knowing that motherhood may still be possible can transform the entire outlook of cancer treatment turning fear into hope. A Message of Hope Today, breast cancer in young women is no longer synonymous with lost fertility or lost dreams. With timely counselling, use of GnRH analogues, cryopreservation techniques, and structured pregnancy planning, many women go on to experience motherhood after cancer. The message to every young woman diagnosed with breast cancer is clear: Pause, dont give up. Cancer may challenge you, but it doesnt have to take away your future.

“Breaking the Delay: The Impact of Awareness in Breast Cancer Care"Why breast cancer in India is still diagnosed lateand how awareness can close the gap Breast cancer is now the most commonly diagnosed cancer among Indian women. It has surpassed cervical cancer to take the number one position in the list of cancers affecting women in India. In 2022, India recorded an estimated 192,020 new breast cancer casesover one in four cancers in womenand 98,337 deaths. For example, an assessment of breast cancer diagnosis in women in AIIMS, one of the largest tertiary-care cancer centres in India between 2014 and 2019 showed that out of 977 patients, only 40 patients were detected with stage I (4%), 326 patients with stage II (33%), 419 with stage III (42%) and 212 with stage IV (21%) breast cancer. Despite improvements in treatment, too many women still arrive late in the care pathway, when cure is harder and cost, complexity, and distress are higher. This newsletter outlines where delays occur, why they persist, what the latest data show, and how well-designed awareness efforts can meaningfully reduce time to diagnosis. What do we mean by delay? Clinically, delays can be separated into three linked intervals: Patient delay: time from first noticing a symptom to first contact with a health worker. Diagnostic (system) delay: time from first presentation to tissue diagnosis. Treatment delay: time from diagnosis to initiation of therapy. In Indian studies from rural and semi-urban settings, median patient delays around 45 days and system delays around 19 days are typical, with wide variation (interquartile ranges often spanning weeks to months). These lags allow tumours to grow and spread, contributing to Indias persistently high burden of locoregionally advanced stage at diagnosis reported across registry-linked analyses. Why are Indian women still presenting late? 1) Low baseline awareness and screening uptake Population-representative data remain stark: only ~0.9% of Indian women aged 3049 report ever having been screened for breast cancer (under the governments NCD program), reflecting negligible coverage of clinical breast examination (CBE) and opportunistic mammography. Beyond screening, awareness of symptoms and risk factors is low in community surveysmany women cannot name a warning sign or risk factor, and breast self-examination (BSE) practice is uncommon. A large majority of women report to have noticed the changes in the breast but ignore them because most of the times the changes are painless to begin with. Many cancerous breast lumps are ignored as hormonal changes, clogged milk duct. They simply wish that the lump will go away in few days. Many women feel embarrassed to consult a doctor when they notice breast lumps. 2) Cultural and social barriers Fear of a cancer label, stigma around breast symptoms, modesty concerns, and competing family/work responsibilities commonly defer help-seeking. Qualitative work from Indian cohorts repeatedly surfaces fatalism, embarrassment, and reliance on home remedies as early steps in a wait-and-watch trajectory that amplifies patient delay. In the largely patriarchal society, womens health is not a priority. Women themselves also put their health on the backburner when it comes to family responsibilities. 3) Access and affordability In many districts, women must travel long distances for clinical evaluation, imaging, and biopsy. Public systems face bottlenecks for ultrasound, mammography, core needle biopsy, and pathology reporting, stretching diagnostic timelines. For the uninsured or under-insured, out-of-pocket costs and lost wages further deter timely care. 4) Program design and capacity gaps Indias population-based screening uses CBE delivered by ASHAs/ANMs from age 30 at 5-year intervals, with referral to primary and district facilities. Implementation assessments highlight low screening priority at Health Wellness Centres, workforce overload, supply gaps, and weak tracking of screen-positive womenall of which limit impact. 5) Provider-side delays Even after first contact, navigation through imaging, biopsy, and surgical/oncology consults can add weeks. Mixed-methods studies depict fragmented pathways and referral loops that extend system delay; where BSE/SBE is absent, the initial presentation can be to non-oncology providers, further prolonging time to diagnosis. What do the numbers say? Burden: Breast cancer is Indias top cancer in women by incidence and mortality. Stage at diagnosis: Multi-registry analyses report a majority diagnosed beyond very-early stages, with consequences for survival and cost. Delays: Typical median patient delay 45 days; system delay 19 days, with substantial variation by setting and socioeconomic status. Screening coverage: 0.9% ever screened for breast cancer among women 3049 in NFHS-5; participation is better in a few southern states but remains low nationally. Can awareness activities really reduce delay? Yeswhen awareness is targeted, practical, and paired with access. Three streams of evidence matter: Community CBE trials show downstaging and mortality benefit. In Mumbais 20-year cluster RCT (151,538 women, 3564 years), biennial CBE by trained health workers plus awareness led to significant downstaging and a ~30% reduction in breast cancer mortality among women 50 (overall mortality reduction ~15%, borderline significance). This demonstrates that awareness + simple examination can shift disease stage and outcomes in real-world Indian communities. Complementary results from Trivandrum show earlier stage at detection with triennial CBE. Awareness campaigns improve knowledge and early-help behaviours. Well-structured campaignsin workplaces, colleges, and community groupssustainably raise knowledge and self-examination practice at 612 months, a prerequisite for shrinking patient delay. Recent focus-group evaluations from North India echo this, showing movement from hesitation to I should get checked when messages are culturally attuned and delivered by trusted messengers. Breast-self-awareness links to shorter delays. Mixed-methods studies find women who regularly check their breasts or who recognize a change earlier reach providers sooner, with measurable reductions in both patient- and system-level delay. Breast cancer awareness that actually shortens time to diagnosis Breast cancer awareness can be seen as a pathway. Awareness programs that hope to make a difference in India might be more impactful if they are shaped around four guiding principles: A. Meet women where they are Consider running community sessions through ASHAs, SHGs, Anganwadi workers, or even factory floors. Messages in local languages, addressing common myths (e.g., a painless lump is harmless), and giving clear next steps such as clinic days or phone numbers could help. Involving men and family decision-makers may also ease issues like transport, time, and funds. Evidence suggests that when messages are credible and immediately relevant, women are more likely to seek help earlier. B. Pair messages with services Awareness days could be turned into screen-and-refer camps that include on-site CBE, ultrasound triage, and direct biopsy scheduling. In resource-limited areas, exploring newer technologies being piloted by public programs might help expand reach and reduce late-stage diagnoses. C. Build fast lanes Hospitals might think about setting up one-stop breast clinics, where CBE, imaging, and biopsy scheduling happen in a single visit. Nurse navigators and simple tools like WhatsApp/SMS reminders could shorten diagnostic intervals. Pre-booked radiology/biopsy slots during awareness drives may prevent backlogs. Studies from India point out that navigation and streamlined referrals are often critical for reducing delay. D. Close the loop with data Hospitals could also choose to track and reflect on: Median patient delay (symptom first visit) Median diagnostic delay (first visit diagnosis) Stage distribution (stage III vs IIIIV) Time-to-treatment initiation Loss-to-follow-up after a positive CBE Looking at these numbers regularly can help turn awareness into a quality-improvement cycle, in line with national screening goals. The bottom line: India faces a large and growing breast cancer burdenand delay is the enemy. But the evidence is clear: awareness that is paired with simple, accessible examination (CBE), rapid referral, and navigated diagnostics can downstage disease and save livesas demonstrated by Indias own cluster randomized trials. For Andromeda Cancer Hospital, this is not just outreach; it is mission to improve the breast health in our society. We organize programs to educate women about the critical knowledge related to breast cancer. If we are able to shorten the journey from first symptom to first consult and from first consult to tissue diagnosis, we will change the survival curve for thousands of Indian womenone timely diagnosis at a time.

Childhood Cancers: A Comprehensive Overview "Small Warriors, Big Battles: Understanding Childhood Cancer Childhood cancers, though relatively rare, represent a profound challenge in paediatric healthcare, affecting thousands of families across the globe each year. Unlike adult cancers, they often arise from unknown causes and progress rapidly, demanding swift diagnosis and specialized treatment. From leukaemia and brain tumours to neuroblastoma and Wilms tumour, these diseases strike at vulnerable ages, often before children can articulate their symptoms. Understanding the risk factors, common types, and evolving treatment landscape is crucial not only for clinicians but also for caregivers and policymakers. This newsletter explores the global and Indian context of childhood cancers, highlighting advances that offer renewed hope. 1. Risk Factors Unlike adult cancers, most childhood cancers do not have well-established environmental or lifestyle risk factors. However, some known contributors include: Genetic mutations: Around 510% of childhood cancers are linked to inherited genetic changes. Infections: Chronic infections like HIV, Epstein-Barr virus, and malaria are associated with increased risk, especially in low- and middle-income countries (LMICs). Radiation exposure: Prenatal or early-life exposure to ionizing radiation may elevate risk. Congenital syndromes: Conditions like Li-Fraumeni syndrome, Down syndrome, and neurofibromatosis are associated with higher cancer susceptibility. Despite extensive research, most childhood cancers arise spontaneously without identifiable external triggers. 2. Common Types of Childhood Cancers Childhood cancers differ significantly from adult cancers in origin and behaviour. The most prevalent types include: Leukaemia: Especially Acute Lymphoblastic Leukaemia (ALL), accounting for nearly 30% of cases. Brain and central nervous system tumours: Including medulloblastomas and gliomas. Lymphomas: Both Hodgkin and non-Hodgkin types. Neuroblastoma: A cancer of nerve tissue, often affecting infants. Wilms tumour: A kidney cancer typically seen in children under 5. Bone cancers: Such as osteosarcoma and Ewing sarcoma. Retinoblastoma: A rare eye cancer, often diagnosed before age 5. 3. Incidence: Global and Indian Globally, an estimated 400,000 children and adolescents (019 years) are diagnosed with cancer annually. The burden varies widely: Region Estimated Cure Rate Key Challenges High-income countries 80% Early diagnosis, access to care LMICs (including India) 30% Delayed diagnosis, treatment abandonment In India, approximately 50,000 new cases are reported each year. Childhood cancers represent about 4% of all cancers in the national registry. Delhi shows the highest age-adjusted incidence rates: 203.1/million (boys) and 125.4/million (girls). 4. Common Age at Risk The paediatric age group is typically defined as 014 years, though some centres extend it to 18 years. Specific cancers tend to peak at different ages: Infants (1 year): Neuroblastoma, retinoblastoma Toddlers (14 years): Wilms tumour, ALL School-age (59 years): Brain tumours, lymphomas Adolescents (1019 years): Bone cancers, Hodgkin lymphoma 5. Common Symptoms Detecting cancer in children is challenging due to symptom overlap with common illnesses. Key warning signs include: Persistent, unexplained weight loss Frequent headaches with morning vomiting Swelling or pain in bones/joints Lumps in abdomen, neck, or chest Whitish appearance in pupil or vision changes Recurrent fevers without infection Excessive bruising or bleeding Fatigue and paleness Awareness among caregivers and primary physicians is crucial for early detection. 6. Genetic Testing Genetic testing plays a growing role in: Identifying predisposition: For families with history of cancer or syndromic features. Guiding treatment: Certain mutations (e.g., TP53, ALK) influence therapy choices. Risk stratification: Helps determine prognosis and recurrence risk. However, access to genetic counselling and testing remains limited in many Indian settings. 7. Diagnosis Diagnosis involves a multidisciplinary approach: Clinical evaluation: History and physical examination. Imaging: MRI, CT scans, PET scans for tumour localization. Biopsy: Essential for histopathological confirmation. Blood tests: Including complete blood count, tumour markers. Bone marrow aspiration: Especially for leukaemia. Timely and accurate diagnosis is often hindered in LMICs due to lack of infrastructure. 8. Treatment Treatment depends on cancer type, stage, and patient age. Modalities include: Chemotherapy: Backbone of paediatric cancer treatment. Surgery: For localized solid tumours. Radiotherapy: Used selectively due to long-term side effects. Stem cell transplant: For high-risk leukaemia and relapsed cancers. Targeted therapy: Emerging options for specific mutations. In India, specialized paediatric oncology units are essential but not uniformly available. 9. Prognosis Prognosis varies by cancer type and healthcare access: High-income countries: Survival rates exceed 80% for many cancers. India: Estimated survival around 70%, but varies widely. Poor prognosis factors: Late-stage presentation Treatment abandonment Toxicity-related deaths Relapse Long-term survivors may face challenges like growth delays, fertility issues, and secondary cancers. 10. Recent Advances Exciting developments are reshaping childhood cancer care: Immunotherapy: CAR-T cell therapy shows promise in relapsed leukaemia. Precision medicine: Genomic profiling enables personalized treatment. Minimally invasive surgery: Reduces recovery time and complications. Digital health tools: Improve follow-up and symptom tracking. Global initiatives: WHOs Global Initiative for Childhood Cancer aims to raise survival to 60% worldwide by 2030. 11. Psychosocial Impact and Support Systems Emotional toll: Childhood cancer affects not just the child but the entire family. Anxiety, depression, and post-traumatic stress are common. Support services: Play therapy, counselling, and parental support groups are vital but underprovided in many Indian hospitals. 12. Healthcare Infrastructure Gaps in India Less than 50% of tertiary hospitals in India offer essential services like brachytherapy, safe chemotherapy preparation, or daycare beds. Only 41.6% of public tertiary hospitals have dedicated paediatric oncology departments. 13. Data Systems and Policy Needs India lacks robust childhood cancer registries and data-driven policies, which hinders planning and resource allocation. WHO emphasizes that data systems are crucial for improving care quality and informing national strategies. 14. Long-Term Survivorship and Late Effects Survivors often face growth delays, cognitive impairments, fertility issues, and increased risk of secondary cancers. There's a growing need for survivorship clinics and long-term follow-up protocols. 15. Prevention and Public Awareness While most childhood cancers can't be prevented, public awareness can reduce delays in diagnosis and treatment abandonment. Campaigns tailored to rural and underserved communities are especially critical. In India, efforts are underway to strengthen paediatric oncology infrastructure, data systems, and training. Childhood cancers, though daunting, are increasingly treatable with timely diagnosis and evolving therapies. Global collaboration, improved access, and scientific innovation offer renewed hope for young patients. By raising awareness and strengthening care systems, we can transform outcomesensuring that every child, regardless of geography, has a fighting chance at life.

Prostate Cancer Today: Statistics and Practical Pearls Prostate Cancer: Risk, Diagnosis, and Management Introduction Prostate cancer is the most common cancer in men worldwide, and its incidence increases with age. While many cases grow slowly and may not cause harm, others can be aggressive and life-threatening. Understanding risk factors, early signs, diagnostic methods, and treatment options is essential for effective management and improved outcomes. Epidemiology and Age-Related Risk Prostate cancer incidence rises steeply with age, with men over 65 at the highest risk. Around six in ten cases are diagnosed in men aged 65 or older, with the median age at diagnosis being 6768 years. Rare before age 40. Sharp rise after age 50. Nearly 43% of new cases occur between 6574 years, and another 18% between 7584 years. This strong association with increasing age underscores prostate cancer as primarily a disease of older men. Risk Factors Established Risk Factors Age: The single most significant factor. Family History: Having a first-degree relative with prostate cancer doubles the risk. Risk is higher if multiple relatives are affected or diagnosed at a young age. Ethnicity: Black men have the highest incidence and mortality. Genetics: BRCA1 and BRCA2 mutations, Lynch syndrome, and other inherited genetic changes increase risk. <div class="ivm-view-attr__img-wrapper "> Lifestyle and Environmental Factors Obesity: Moderately increases risk and is associated with more aggressive disease. Diet: High intake of red meat and dairy, and low intake of fruits and vegetables, may play a role. Lifestyle changes: Sedentary habits and urbanization contribute to rising incidence in developing countries. Prostate Cancer in India In India, incidence is very low below age 55 but rises sharply after this age, peaking in men over 65. Age-specific incidence rates from cancer registries show: Below 1 per 100,000 in men under 55. Rising to 1015 per 100,000 in those over 65. Recent trends indicate a gradual rise among men aged 5564, and to a lesser extent in younger groups (3544) in large cities, reflecting lifestyle changes. Young-onset prostate cancer, while still rare, is increasing in urban India and often presents at a more advanced stage, with higher mortality due to delayed diagnosis. Symptoms and Early Detection Early Stage Most early prostate cancers cause no symptoms and are detected through screening. When present, symptoms often involve urinary changes: Difficulty starting urination. Weak or interrupted urine flow. Frequent urination, especially at night. Feeling of incomplete bladder emptying. Blood in urine or semen. Painful urination or erectile dysfunction. <div class="ivm-view-attr__img-wrapper "> These are not specific to cancer and may also occur in benign prostate conditions. When to Consult a Doctor Men should seek medical evaluation if urinary symptoms persist, especially if accompanied by: Bone pain. Unexplained weight loss. Erectile dysfunction. Men over 50or younger men with family history or high riskshould discuss screening with their doctors. Diagnosis Initial Evaluation Digital Rectal Exam (DRE): Detects abnormalities in prostate size and texture. Prostate-Specific Antigen (PSA) Test: Elevated levels may indicate cancer but can also occur in benign conditions. Imaging and Biopsy Multiparametric MRI: Identifies suspicious areas for targeted biopsy. Biopsy: Transrectal or transperineal ultrasound-guided sampling is required for confirmation and grading. Staging Cancer staging determines the extent of disease using: PSMA PET-CT (highly sensitive). Bone scans, CT, and MRI. Staging is crucial for treatment planning. <div class="ivm-view-attr__img-wrapper "> Biomarkers Beyond PSA, several biomarkers aid diagnosis and prognosis: PCA3: A urine test highly specific for prostate cancer. AMACR: A tissue marker often positive in biopsy pathology. PTEN loss and TMPRSS2-ERG fusion: Associated with prognosis and therapy response. Emerging biomarkers: Exosomal proteins, microRNAs, and DNA methylation profiles offer potential for precision medicine. Treatment Options Treatment depends on cancer stage, aggressiveness, and patient health. Active Surveillance For low-risk localized cancers, close monitoring avoids or delays treatment. Regular PSA tests, MRIs, and biopsies are done, with curative treatment initiated if disease progresses. This strategy balances effective control with minimizing side effects. Surgery Radical Prostatectomy removes the prostate gland and sometimes nearby tissues. Best suited for healthy men with localized cancer. Risks include urinary incontinence and erectile dysfunction. Requires hospitalization but offers excellent long-term control. Radiation Therapy Radiation destroys cancer cells using external beams (EBRT) or internal sources (brachytherapy). Less risk of urinary incontinence compared to surgery. More likely to cause bowel-related issues. Highly effective for localized disease. Hormone Therapy Androgen deprivation therapy reduces testosterone, slowing cancer growth. Used for advanced or recurrent disease, often in combination with other treatments. Chemotherapy Reserved for advanced or castration-resistant prostate cancer. Novel Therapies High-Intensity Focused Ultrasound (HIFU). Immunotherapy in selected cases. PARP inhibitors for men with BRCA mutations. PSMA-targeted radioligand therapy for advanced disease. Surgery vs Radiation: Key Comparisons Both surgery and radiation offer similar long-term survival for localized cancer. Surgery: Higher risk of urinary incontinence and erectile dysfunction but relieves obstruction. Radiation: Fewer urinary side effects but more bowel issues; ED develops gradually over time. Choice depends on cancer stage, patient health, and personal preference. Side Effects of Treatment Urinary Incontinence After Surgery: Occurs in 622% of men, especially older or obese patients. Improves with time; pelvic floor therapy or surgical correction may be required. After Radiation: Less common (10% at 3 years) but can occur late due to bladder damage. Erectile Dysfunction After Surgery: Very common due to nerve injury; recovery may take up to 18 months. Nerve-sparing techniques and younger age improve outcomes. After Radiation: Gradual onset, with 1726% affected at 2 years. Bladder Function After Radiotherapy Reduced bladder compliance and capacity. Increased urgency and frequency of urination. Persistent outlet obstruction since the prostate remains in place. Risk of late complications such as urethral stricture and radiation cystitis. Role of PSMA PET in Management PSMA PET is a breakthrough imaging tool that detects prostate cancer with high sensitivity. Applications: Accurate staging at diagnosis. Detection of recurrence when PSA rises after treatment. Improved treatment planning with tailored strategies. Lower radiation exposure and fewer inconclusive results compared to CT or bone scans. FDA-approved tracers and global guidelines now endorse PSMA PET as a standard in prostate cancer care. Advances in Prostate Cancer Treatment Recent innovations have improved outcomes and reduced side effects: Robotic-assisted surgery offers precision with faster recovery. Advanced radiotherapy techniques minimize collateral damage. Novel systemic therapies (androgen receptor inhibitors, PARP inhibitors). PSMA-targeted radioligand therapy for advanced disease. Immunotherapy trials show promise in early-stage and aggressive cases. These advances reflect a move toward personalized and targeted treatment strategies. <div class="ivm-view-attr__img-wrapper "> Prognosis Prostate cancer prognosis depends on stage, grade, and health at diagnosis. Localized disease: Excellent, with nearly 100% 5-year survival. Advanced disease: Poorer, with around 38% 5-year survival in metastatic cases. Other important prognostic factors include: Gleason score PSA levels Tumour volume Surgical margins Molecular markers (p53, Ki-67) Younger men and those in good overall health have better outcomes. Despite many cases being slow-growing, risk stratification is essential to tailor therapy. Conclusion Prostate cancer is predominantly a disease of older men but is rising in younger age groups in India and worldwide due to lifestyle changes and better detection. Early diagnosis through PSA, DRE, and advanced imaging like PSMA PET allows timely and tailored treatment. With evolving therapiesranging from active surveillance to precision medicineoutcomes are improving. Individualized care remains the cornerstone of balancing cancer control with quality of life.

Nuclear Medicine in Oncology: Lighting the Way in Cancer Diagnosis & Therapy The Story Begins with a Tracer The foundation of nuclear medicine goes back to a groundbreaking idea from Hungarian chemist George de Hevesy in the early 20th century, a Nobel Prizewinning scientist and also widely recognized as the "father of nuclear medicine" Hevesy discovered that minute quantities of radioactive compounds (radiopharmaceuticals) / radioactive tracers could be used to follow chemical processes inside living beingsjust like adding a drop of dye to water to see where it flows. In his famous experiment, he used tiny amounts of radioactive isotopes to study how plants absorbed nutrients. Thistracer principle is still the basis of nuclear medicine today: ➡️ Use a safe radioactive compound (called a radiotracer) that behaves like natural substances in the body. ➡️ Track its path with special cameras. ➡️ Learn how organs and diseases functionfrom the inside out. <div class="ivm-view-attr__img-wrapper "> The Fundamental Principle of Nuclear Medicine What is Nuclear Medicine? Nuclear medicine is a branch of medical imaging and therapy that uses small amounts of radioactive materials (called radiotracers) to diagnose and treat diseases, especially cancer. These tracers are injected, swallowed, or inhaled, and they target specific organs or tissues. Special cameras detect the radiation emitted, creating images that show how your body is functioning at a molecular levelnot just its structure. Unlike X-rays or MRI that show body structures, nuclear medicine looks at how the body works at a cellular level - like how cells are metabolizing or if a tumor is active. Small amounts ofradioactive tracers (safe, medical-grade) are used. Special scanners detect these tracers and create detailed images. The result? Doctors dont just seewhere something is, but also how active it is. It has two main arms:1. Imaging using: Conventional Nuclear Medicine (Gamma Camera / SPECT) Molecular Imaging (PET-CT) 2. NM therapy or now popularly known as Theranostics (Diagnosis + Therapy with the same molecule) Conventional Nuclear Medicine The Gamma Camera Era Uses gamma cameras to detect radioactive tracers and Produce images of organ function. Common tracers: 99mTc (Technetium-99m) based RPs most widely used isotope globallyThe workhorse tracer, used in over 80% of procedures. Used for bone scans, renal scans, cardiac scans, thyroid scans. Iodine I-123 / I-131: Benign and malignant thyroid diseases - Targets thyroid tissue. In diagnosis, it scans for thyroid cancer; in therapy, higher doses destroy cancerous cells. Helps in cancer by: Detecting bone metastases (spread of cancer to bones). Assessing thyroid cancer. PET-CT The Molecular Imaging Revolution PET-CT combines positron emission tomography (PET) with CT. Shows both function (PET) and structure (CT) in one scan. Uses radiotracers that mimic natural body chemicals or target receptors in various physiological and patholigcal conditions. Common PET tracers in cancer: 18F-FDG (Fluorodeoxyglucosewith F-18) Mimics sugar, detects sugar-hungry cancer cells and used in most of the cancers including lung, lymphoma, breast and colorectal cancers. 68Ga-PSMA prostate cancer. 68Ga-DOTATATE neuroendocrine tumors. FES (Fluoroestradiol) breast cancer (estrogen receptor imaging). Role in Cancer Diagnosis 👉PET-CT is often called the GPS for cancer, guiding doctors at every step: Early detection: Using various metabolic and functional processes such as FDG PET scan targetting glucose metabolism: Cancer cells consume more energynuclear scans pick this up early. Accurate staging: Shows if cancer has spread. Treatment planning: Helps doctors decide surgery, chemotherapy, or radiation approaches. Treatment Response Assessment: Shows if cancer is responding or not to treatment Follow-up: Detects recurrence earlier than most tests. Role in Cancer Therapy: 🎯 Theranostics Treat What You See and Diagnose and Treat in One Go Nuclear medicine is not just about diagnosisit can also treat cancer. Theranostics = Therapy + Diagnostics. Uses the same molecule for both diagnosis and treatment, just with different isotopes, For e.g. 68GaPSMA for Prostate cancer staging using PET CT and 177LuPSMA PRLT therapy for progressive and metastatic CRPC prostate cancer. It's personalized medicine at its best: "See it, then zap it." <div class="ivm-view-attr__img-wrapper "> Two Aspects of Nuclear Medicine Targeted therapy: Radioactive medicines deliver treatment directly to cancer cells while sparing most healthy tissue. Used inthyroid cancer, prostate cancer, lymphomas, and neuroendocrine tumors. Think of it as asmart bombprecise and powerful. <div class="ivm-view-attr__img-wrapper "> Past, Present and Future of Theranostics Clinical impact: Lu-177 PSMA therapy has shown 40% reduction in risk of death in advanced prostate cancer (VISION trial). NETTER-1 trial showed 79% progression-free survival improvement with Lu-177 DOTATATE in neuroendocrine tumors. In India, more than 10,000 Lu-177 therapies have been performed in the last 5 years, positioning the country as a regional hub for theranostics. The Numbers Nuclear Medicine Worldwide : Nuclear medicine is booming, driven by aging populations and cancer rises. Diagnostic Nuclear Medicine: ~40 million (4 crore) procedures annually worldwide. USA: ~20 million scans/year. India: ~0.51 million scans/year (rapidly growing). Therapeutic Nuclear Medicine: In 2023,over 100,000 theranostic procedures were performed globally, with rapid growth in prostate and neuroendocrine treatments. Growing at1015% annually worldwide. Theranostics centers expanding rapidly, especially in prostate and neuroendocrine cancer treatment. Market value: $10.19B in 2024, projected to $42B by 2032 (CAGR ~19%). Theranostics segment growing fastest at 13-15% CAGR. USA: $5.12B in 2023, to $16.85B by 2033 (CAGR 12.6%). High adoption of PET-CT (over 2,000 scanners). India: Rapid growth with 300+ centers. ~1-2 million procedures/year. Market to $1.07B by 2030 (CAGR 10.9%), fueled by affordable tech and rising cancer cases (1.4M new/year). Therapeutic procedures (like radioiodine therapy) grew 20% globally post-COVID, with India seeing 25% annual increase due to better access. Future: Bright and Innovative By 2030, theranostics could dominate cancer care. Prospects include: Expansion to Lung, breast, brain, pancreatic, and ovarian cancers. Alpha emitters (like Ac-225) for resistant cancers. AI-integrated imaging for smarter imaging interpretation, predictive response modeling and faster, more accurate targeting. Combination with immunotherapy. ImmunoPET tracers: tracking immune checkpoint inhibitors in real time Personalized dosimetry: tailoring therapy dose to maximize tumor kill minimize toxicity Challenges: Supply chain for rare isotopes, but advancements in cyclotron production are helping. Myths vs Facts Myth: Nuclear medicine is unsafe because of radiation. ✅ Fact: Radiation doses are carefully regulated, often equal to or less than a CT scan. It is safe, regulated, and used worldwide for decades. Doses are low a PET scan is like 2-3 years of natural background radiation. Tracers decay fast (hours/days), and benefits outweigh risks. Myth: The radioactivity stays in your body forever.✅Fact: Most tracers are eliminated naturally within days. No long-term buildup.Myth: It's painful or invasive.✅Fact: Just an IV injection or pillless invasive than surgery, no pain beyond a needle prick. Myth: It causes cancer✅Fact: Risk is minimal (1 in 10,000 for diagnostics). It's used to fight cancer, not cause it.Myth: Only for end-stage cancer.✅Fact: Great for early detection and monitoring, improving survival rates by 20-30% in many cases.Myth: PET-CT replaces all other scans. ✅ Fact: Different scans answer different questions. PET-CT complements, not replaces. Myth: Once treated with radiotheranostics, you glow or are radioactive. ✅ Fact: The radiation is medical-grade, controlled, and leaves the body safely. Why It Matters for PatientsFor patients, nuclear medicine means: Less invasive testsMore confidence in diagnosis Tailored Personalised treatmentBetter chances of cure and survival Take-Home Messages Nuclear medicine is not science fictionitsscience saving lives daily. It allows doctors tosee cancer earlier, track it better, and treat it smarter. FromHevesys tracer principle to modern PET-CT and theranostics, the field has grown into a cornerstone of cancer care. India is catching up fast with global trends, and access is expanding. The future promisespersonalized, precise cancer care with nuclear medicine at its heart. Bust the myths: It's safe, precise, and life-saving. Nuclear medicine is like a torchlight in the dark tunnel of cancerhelping doctors see clearly, act precisely, and give patients hope. Nuclear medicine is not just scienceits a blend of technology and compassion, guiding modern cancer care. Next time you hear about PET scans or targeted radiotherapy, remembertheyre part of a powerful field called nuclear medicine that combines vision with cure. Have you or your loved one ever had a PET-CT or heard about nuclear medicine therapy? Share your thoughts in the comments.By Dr. Aashish Gambhir, Director Head, Nuclear Medicine Andromeda Cancer Hospital

The (Rising) Burden of Cancer What is causing this silent epidemic? Cancer is one of the leading non-communicable diseases globally. Further, the burden of cancer is rising continuously. While significant progress has happened in early diagnosis and treatment of cancer, the burden of death due to cancer is still high. Cancer is the 2nd leading cause of death worldwide and causes nearly 15 to 16% of all deaths. In India too, cancer is a major contributor to the causes of death, 2nd overall in urban areas and 4th overall in rural areas. The cliched saying is A stitch in time saves nine but it may be highly relevant when it comes to cancer. Preventing is cancer is theoretically much easier than treating a cancer. However, each and every member of the society needs to be aware of the causes of cancer. Individual action and commitment plays an important role in cancer prevention. Government policies and programs are important but can not work in isolation without public participation. With this background, we are sharing the list of major causes of cancer globally and also highlight their importance based on gender. Recognized Causes and Risk Factors for Human Cancer A. Lifestyle-related Tobacco use (smoked and smokeless) Alcohol consumption Dietary factors: processed/red meat, low fruits/vegetables, obesity-promoting diets Obesity / overweight Physical inactivity B. Environmental and occupational Air pollution (PM2.5, diesel exhaust, indoor coal smoke) Occupational exposures: asbestos, silica, benzene, formaldehyde, wood dust, vinyl chloride, certain metals (arsenic, cadmium, chromium, nickel) Radiation: ionizing radiation (X-rays, gamma rays, radon), ultraviolet radiation (sunlight, tanning beds) C. Biological / infectious agents Viruses: HPV, HBV, HCV, EBV, HTLV-1, KSHV, MCPyV Bacteria: Helicobacter pylori Parasites: Opisthorchis viverrini, Clonorchis sinensis, Schistosoma haematobium D. Hormonal and reproductive Endogenous hormones: prolonged estrogen exposure (early menarche, late menopause, nulliparity, hormone replacement) Exogenous hormones/medications: oral contraceptives, menopausal hormone therapy, DES Immunosuppressive drugs (tacrolimus, azathioprine) E. Genetic and host-related Inherited cancer syndromes (e.g., BRCA1/2, Lynch, Li-Fraumeni) Family history (polygenic risk) Ageing (strongest single risk factor, reflects cumulative mutations and immune decline) Cancer Risk Factors Grouped by Gender Predominantly male cancers / risks Tobacco use (still higher in men globally lung, head neck, bladder, esophagus, pancreas) Occupational exposures (asbestos, silica, diesel exhaust, metals historically more in men) Alcohol use (higher consumption rates in men) HPV oropharyngeal cancer risk increasingly seen in men <div class="ivm-view-attr__img-wrapper "> Predominantly female cancers / risks Reproductive/hormonal factors (estrogen/progesterone exposure breast, endometrial, ovarian) HPV cervical cancer (exclusively female) Hormone therapy (HRT, OCPs, DES) <div class="ivm-view-attr__img-wrapper "> Both men and women Tobacco, alcohol, obesity, diet, physical inactivity Air pollution, radiation, environmental exposures Infectious causes: HBV/HCV (liver), EBV (lymphoma/nasopharynx), H. pylori (stomach), parasites Genetic predispositions <div class="ivm-view-attr__img-wrapper "> Relative Contribution to Cancer Burden (Attributable Fraction) Global estimates (WHO / IARC / GLOBOCAN; varies by region): Tobacco ~22% of all cancer deaths worldwide (8 million deaths annually). Causes lung, head neck, bladder, esophagus, pancreas, stomach, kidney. Infections ~1315% of cancers globally, higher in developing countries. HPV, HBV, HCV, H. pylori dominate. Alcohol ~56% of cancers worldwide. Strong links: oral cavity, pharynx, larynx, esophagus, liver, breast, colorectum. Obesity/overweight physical inactivity ~58% globally. Strong for breast (postmenopausal), colorectal, endometrial, pancreas, kidney, liver. Diet (low fruits/vegetables, high processed meat, low fiber, high salt) ~5%. Occupational exposures ~35% of cancers (but higher in men in industrialized areas). Air pollution (ambient + household) ~23% globally; larger share in Asia. Radiation (ionizing + UV) ~2%. UV is major for skin cancers (melanoma, squamous, basal). Genetic predisposition ~510% of cancers due to inherited mutations. Ranking by Estimated Impact (Global cancer burden) Tobacco (22%) Infections (1315%) Alcohol (56%) Obesity / overweight / inactivity (58%) Dietary factors (5%) Occupational exposures (35%) Air pollution (23%) Radiation (2%) Genetic predisposition (510% but varies by cancer type) <div class="ivm-view-attr__img-wrapper "> Key Takeaways: The largest preventable causes globally are tobacco, infections, alcohol, and obesity-related factors. Men: Major risk related to tobacco, alcohol, and occupational risk factors. Women: Major risk related to reproductive/hormonal factors, HPV, obesity-linked cancers. Both sexes: Diet, infections, air pollution, and radiation.

The Challenges of Breast Cancer in India Introduction Breast cancer is the commonest cancer of women globally and in India. According to GLOBOCAN 2022, breast cancer accounts for nearly 23 lakh new cases each year. In India, nearly 2 lakh cases of breast cancer are diagnosed every year. In India, 1 in 28 women will develop breast cancer during their lifetime. Due to intense research efforts, breast cancer has become highly curable. Unfortunately, 5060% of breast cancer cases in India are still diagnosed at Stage 3 or beyond, compared to less than 10- 20% in high-income countries. Five-year survival rate in western countries is nearly 85 to 90%. However, India lags behind significantly in this regard: the five-year survival figure is around 60% only in India. The poor outcomes of breast cancer treatment in India, as compared to developed countries, stem from a combination of medical, social, infrastructural, and economic factors which can be broadly grouped into two as patient factors and system factors.Reasons for Worse Survival of Breast Cancer Patients in India Late diagnosis of breast cancer Lack of access to standardized high quality breast cancer care for a large proportion of breast cancer patients The problem of delay in diagnosis can be managed at the patient (society) level by spreading awareness, guiding them to early symptoms and signs of breast cancer, educating them about breast self-examination, encouraging them to seek medical help early.The problem of delay in diagnosis at the level of healthcare system needs multi-pronged efforts. It is important for the clinicians who see patients with breast symptoms to understand that early diagnosis and prompt initiation of treatment are critical for successful outcome of breast cancer treatment. Every clinician must know that for early and accurate diagnosis, the most reliable step is triple assessment clinical examination, imaging, and pathological confirmation of diagnosis by biopsy. Clinical ExaminationA detailed history (age, family history, duration, changes in size) and systematic clinical examination of the breasts and axillae to detect lumps, skin changes, nipple retraction, discharge, or palpable nodes. Imaging Mammography: gold standard for women over 40 Ultrasound: especially useful for younger women with dense breasts MRI: reserved for complex cases, multi-focal disease, or inconclusive findings. Pathological Assessment Image guided core needle biopsy, which gives not just diagnosis but tumour grade, receptor status (ER, PR, HER2), all this information is essential for treatment planning. When all three correlate, the diagnostic accuracy exceeds 99% minimizing false negatives and false positives. <div class="ivm-view-attr__img-wrapper "> Triple Assessment for Breast Cancer (Examination, Imaging, Biopsy) Challenges in Breast Cancer Care in India In this article, we would like to describe some of the challenges we perceive (as breast specialists) which define the breast cancer care in our country. Lack of Trained Breast Specialists Breast cancer care is now a recognized specialty in India, and many young doctors are taking it up. However, most women with breast symptoms first visit healthcare providers who are not trained in breast examination or cancer screening. Many healthcare providers lack training in proper breast examination. Triple assessment (clinical exam + imaging + biopsy) is not routinely followed. Important signs like skin changes or nipple retraction are missed. Breast lumps are often dismissed as Breast pain is treated casually with Vitamin E or evening primrose oil without proper tests. Advanced cancers are mistaken for mastitis/breast infection. Breast cancers during pregnancy are mostly misdiagnosed as pregnancy associated breast changes. Many doctors manage breast cancers themselves despite not having the right skills. This casual approach, poor clinical examination skills, lack of awareness about triple assessment (clinical exam, imaging, and biopsy), and wrong interpretation of symptoms lead to diagnostic delays and worse outcomes. It is necessary to train and sensitize healthcare providers to detect and refer suspected cases early. Problems in Breast Imaging and ReportingStandards of breast imaging in India vary widely, especially between urban and rural centres. Many reports dont follow BIRADS guidelines or assign wrong categories. Indian women have denser breasts, making mammograms harder to interpret. Poor communication between doctors and radiologists, outdated machines, and shortage of trained breast radiologists add to the problem. In rural areas, lack of modern imaging and expert reporting means more women are diagnosed late. Younger women (more likely to have triple-negative cancers) often get benign-sounding reports, leading to missed diagnoses. Continued Use of FNAC (Fine Needle Aspiration Cytology) for diagnosis and planning treatmentAlthough once common, FNAC has major drawbacks: Less accurate than core needle biopsy (more false negatives). Does not give enough tissue for ER/PR/Her2/Ki67 testing. Cannot confirm invasion or grade the tumour. No information on margins, lymphovascular invasion, or surrounding tissue. Sampling errors are common, leading to missed cancers. Overuse of Direct Excision Biopsies without Proper AssessmentMany women are advised to have their lump removed directly without imaging or core biopsy because breast surgery is wrongly thought to be easy. Myths about biopsy spreading cancer make patients agree to excision. Sometimes the removed lump is not sent for pathology, denying diagnosis. Specimens are often removed into pieces or not oriented for margins, making accurate size and margin clearance assessment impossible. Poorly placed surgical incisions may prevent breast conservation later. Axillary node assessment is not done, requiring another surgery. These issues can delay treatment and reduce chances of cure. Starting Treatment without knowing IHC Results (Biological profile of the individuals breast cancer)Today, breast cancer treatment is personalized. Information on tumour biology (ER/PR/Her2/Ki67) and stage is essential for planning. Patients with certain subtypes (triple-negative, Her2-positive) or large tumours benefit from neoadjuvant systemic therapy before surgery. Without these details, outdated mastectomy first approaches deny patients the advantages of modern treatment. Overuse of MastectomyMany women undergo mastectomy solely based on FNAC results, sometimes even when its a false-positive. Breast conservation surgery (BCS) is equally safe for early cancers, but lack of surgeon training, old beliefs, and ignorance mean that 2/3 of breast cancer surgeries in India are still mastectomies. Mastectomy can cause lifelong psychological distress. Although, breast reconstruction can be safely performed after mastectomy, it requires advanced surgical skills, extra days of hospitalization and post-surgical recovery and significantly additional cost compared to the breast conservation surgery. Incomplete MastectomiesWhen performed by untrained surgeons, mastectomy may leave significant breast tissue or lymph nodes behind. This leads to high recurrence risk and rapid disease progression. Completion surgery is technically difficult and may prevent breast reconstruction. Scarring and poor incision placement complicate future treatments. Delays in adjuvant therapy worsen prognosis. Very limited availability of resources and skills for sentinel node biopsyWithout SLNB, many women with early breast cancer undergo full axillary lymph node dissection, even when nodes are not involved. This causes high risk of complications such as arm swelling (lymphedema), shoulder stiffness, numbness, chronic pain, and higher risk of wound problems. It prolongs recovery, lowers quality of life, and leaves lasting disability. SLNB is a safer, less invasive, guideline-recommended procedure. Many Indian patients face avoidable harm and overtreatment due to this. Issues related to systemic Therapy for Breast Cancer Drug availability cost barriers: Newer targeted drugs and supportive medicines may be unaffordable or unavailable for many patients. Incomplete biological profiling: ER, PR, Her2, and Ki67 tests are sometimes not done before starting chemotherapy, leading to non-personalized treatment. Use of outdated regimens: In smaller centres, older protocols may still be used instead of evidence-based modern regimens. Risk of errors high toxicity: Incorrect dosing, poor monitoring, and lack of proper supportive care can cause preventable side effects. Infrastructure limitations: Many places lack dedicated day-care chemotherapy units, proper infection control, and trained oncology nurses. Inadequate patient counselling: Patients may not receive enough guidance on side effects, fertility preservation, or the importance of completing all cycles. Poor adherence to treatment: Due to side effects, cost, or lack of awareness, some patients discontinue therapy early, reducing chances of cure. Issues related to Radiotherapy for Breast CancerLimited availability of advanced technology: Many centres still use outdated cobalt machines instead of modern linear accelerators with 3DCRT, IMRT, or IGRT capabilities. Geographic and access barriers: Radiotherapy facilities are concentrated in larger cities, forcing rural patients to travel long distances daily for several weeks. Long waiting times: High patient load and limited machines lead to delays in starting treatment, which can worsen outcomes. Lack of breast-specific techniques: Inadequate use of advanced methods like deep inspiration breath-hold (DIBH) to protect the heart and lungs in left-sided cancers. Inconsistent treatment quality: Variation in contouring, planning, and dose delivery between centres due to lack of standard protocols or quality audits. Shortage of trained staff: Limited numbers of radiation oncologists, physicists, and technologists with specialized breast cancer training. Side effect management gaps: Insufficient counselling and follow-up for managing skin reactions, fatigue, lymphedema, and late toxicities. Financial burden: High cost of advanced radiotherapy techniques and travel/accommodation expenses during prolonged treatment courses. Challenges in Genetic Counselling and Testing for Breast Cancer patients.Low awareness: Many patients and even healthcare providers are unaware of the role of BRCA and other genetic mutations in breast cancer risk. Limited availability of trained counsellors: Very few centres have qualified genetic counsellors to guide patients and families. High cost of testing: Genetic tests are expensive, often not covered by insurance, and unaffordable for many patients. Access barriers: Testing facilities are concentrated in urban centres, limiting availability for rural populations. Cultural and social stigma: Fear of discrimination, marriage-related concerns, and family pressure discourage many from testing. Poor integration into routine care: Genetic risk assessment is not consistently incorporated into breast cancer evaluation and follow-up. Lack of pre- and post-test counselling: Inadequate explanation of test implications can lead to anxiety, misinterpretation, or misuse of results. Limited cascade testing: Family members at risk are rarely offered or encouraged to undergo testing. Data privacy concerns: Fear of genetic information misuse due to weak legal safeguards. Missed prevention opportunities: Without testing, high-risk women lose the chance for preventive measures such as enhanced screening, chemoprevention, or prophylactic surgery. Concerns Related to Recurrence Score Testing in Breast CancerHigh cost: These tests are expensive and often not covered by insurance, making them unaffordable for many patients. Limited availability in India:Most samples are sent abroad, increasing cost and turnaround time. Delay in treatment decisions: Waiting for results can postpone the start of adjuvant therapy. Lack of awareness: Many oncologists and patients are unfamiliar with the availability, benefits, and limitations of these tests. Unclear applicability in all populations: Most validation studies are from Western populations; Indian-specific outcome data is limited. Infrastructure and logistics: Sample collection, preservation, and international shipping may be challenging, especially in smaller centres. Patient anxiety: Misunderstanding the meaning of recurrence scores can cause unnecessary worry or false reassurance. Limited use in public sector: Government hospitals rarely offer or recommend such tests due to cost constraints. Ethical and equity concerns: Only wealthier patients can access these tools, creating disparities in personalized cancer care. In summary: Improving breast cancer outcomes in India requires: Training doctors in proper clinical and diagnostic pathways. Enforcing quality standards in imaging and reporting. Phasing out FNAC for diagnosis in favour of core biopsy. Working towards establishing early diagnosis and prompt initiation of treatment. Making breast cancer treatment available and affordable to all the patients Avoiding unnecessary or poorly performed surgeries. Multi-disciplinary approach to ensure that the treatment decisions are made after full pathological and biological assessment. Ensuring oncological safety and working towards preserving long term quality of life of the survivors. <div class="ivm-view-attr__img-wrapper "> Multi-disciplinary Board Meeting

Obesity and Cancer — What Everyone Should Know?(Eat and exercise your way to a healthy life.) Welcome from Andromeda Cancer Hospital At Andromeda Cancer Hospital, our mission is to bring useful health information straight to our community. Today, we tackle an important, often misunderstood topic: the connection between obesity and cancer. With obesity rates rising and cancer cases growing in Haryana and across India, its the right time to learn and take charge of our health. Obesity is assessed by BMI but normal weight obesity also occurs and truncal fat is more harmful. What Causes ObesityObesity develops from a mix of different factors working together. While eating more calories than the body burns is a major cause, theres much more to it. Here are some of the key contributors: Unhealthy diet and overeating: Consistently eating more calories than needed, especially from high-sugar and processed foods. Lack of physical activity: Sedentary lifestyles make it easier to gain weight. Genetics: Family history can influence how your body stores fat and uses energy. Hormonal imbalances: Conditions like hypothyroidism or changes in hormones can affect weight. Medical conditions and medications: Some illnesses and medicines can contribute to weight gain. Emotional stress: Stress or emotional eating may lead to consuming excess calories. Environmental and lifestyle factors: Easy access to unhealthy foods, busy routines, and lack of resources for exercise also play a part. Obesity has multiple underlying causes In summary, obesity is usually the result of a complex interplay between lifestyle habits, biology, medical issues, and our environment. Quick Facts: The burden of obesity is rising all over the world. In India, over 135 million people are affected by obesity. The burden has increase by nearly 200% in last two decades and is expected to double in the next 10 to 15 years. How Are Obesity and Cancer Connected?Many people dont realize that carrying extra weight can actually increase ones risk of developing cancer. Research has shown that obesity is a risk factor for several types of cancers. WHO and IARC have identified 13 different cancers whose risk is increased by obesity. These include. Uterine (endometrial) cancer Breast cancer (especially after menopause) Ovarian Cancer Cancer of oesophagus Colon and rectum cancer Liver cancer Gallbladder cancer Pancreatic cancer Stomach cancer Kidney cancer Multiple myeloma Thyroid cancer Meningioma See the Connection Between Obesity and Cancer:Why Does Obesity Increase Cancer Risk? You dont need to be a scientist to understand the basic idea: Think of your body like a car engine. If its overloaded and running too hot, problems will follow. Extra Fat Increases Inflammation: Chronic, low-level inflammation caused by obesity can damage cells and lead to cancer. Growth factors: Excess fat in the body leads to insulin resistance and increases the release of insulin and related growth factors in response to food. These growth factors increase the cancer risk. Hormone Changes: Excess fat converts some hormone released from the adrenals to active oestrogens and the higher levels of postmenopausal oestrogens are associated with higher risk of cancers such as breast cancer, endometrial cancer, etc. Impact on Immunity: Obesity can weaken your immune system, making it harder to detect and fight off cancer cells. What Can You Do? Actionable TipsYou have more power than you think! Start with small, lasting changes: Choose local, seasonal fruits and vegetables. Try to add millet (bajra, jowar) and pulses to your meals. Limit processed foods and sugary drinks. Move more every day. Even a 30-minute walk in your neighbourhood or some light yoga can make a big difference. Exercising is important for obesity control. Diet alone will not be sufficient in the long run. Regular health checkups. Early detection saves lives! Dont hesitate to consult our team for advice. Family support.Involve your loved ones in healthy habits together, its easier. What the other harms in cancer patients who are obese?The problems dont stop at increasing the risk of cancer. Cancer treatment is more problematic in obese patients, complications of treatment are higher, and the treatment may be less effective. Obese patients may have higher risk of cancer recurrence. Is it possible to get out of this vicious cycle?Yes, if you can control your weight, you can reduce your risk of cancer. Reduction in weight after cancer diagnosis and treatment also reduces the side effects of cancer treatment, improves long term survival and improves quality of life.Various approaches including exercise, dietary modifications, anti-obesity medications, bariatric surgery can all be used depending upon the individual patients needs and choices. At Andromeda Cancer Hospital, we offer nutrition guidance, tailored cancer screenings, and weight management support. Our doors are always open for you and your family. QA Busting Common MythsLets clear up some common misunderstandings:Myth 1: Only junk food makes you obese.Reality: While diet matters, other factors like low physical activity, genetics, and even stress play important roles.Myth 2: Thin people dont get cancer, and overweight people always do.Reality: Anyone can get cancer but being obese increases risk for certain cancers. Maintaining a healthy weight lowers (but doesnt eliminate) your risk.Do you have questions or want to share your story? Wed love to hear from you. Write to us or visit Andromeda Cancer Hospital lets fight cancer together. For free health talks, screenings, and support, contact us at 9138111625. Catch our next newsletter in your LinkedIn feed! Subscribe to the newsletter. Stay informed. Follow Andromeda Cancer Hospital here on LinkedIn for trusted tips, inspiring stories, and upcoming events.Have a question or a topic youd like us to cover? Comment below or message us directly! Together, lets build a healthier India, healthier Haryana and healthier Sonipat. Let us fight cancer at all levels, prevent it, diagnose it early, treat it better and help patients live a happy and healthy cancer free life. Please visit our YouTube channel for videos on Obesity and Cancer. You can also visit and subscribe to the YouTube channel for regular informative videos about cancer awareness.

Immune Therapy in Cancer: mRNA Vaccines.....What is mRNA? mRNA (messenger RNA or ribonucleic acid) is polymeric molecule produced in the cells by a process of transcription using DNA. mRNA is a template used for synthesis of proteins. The proteins then get modified in various ways and serve their diverse functions. Some of the proteins serve as antigens that are recognized by immune cells of the body and body can mount an immune defence against these antigens. What are mRNA vaccines and how do they work? An mRNA vaccine is a revolutionary type of immunization that uses mRNA prepared in the laboratory and injected. It instructs the body cells to produce a viral or tumor-related protein. This stimulates the immune system to build both antibody (humoral) and T-cell (cellular) responses.Steps in the process for mRNA vaccine preparation and usage Antigens have to be identified from the viral pathogens or cancer cells mRNA are produced in the laboratory using equipment that can generate mRNA molecules in the instructed sequence. The mRNA molecules are packaged in lipid nanoparticles (LNPs). The vaccine is administered via intramuscular injection. Cells translate the mRNA to produce the target antigen (e.g., SARS‑CoV‑2 spike protein). When the antigen appears on the cell surface, the immune system recognizes it as foreign and activates adaptive immunity. The mRNA is degraded afterward (and does mRNA vaccines across different diseases. Infectious diseases: Viral Targets: COVID‑19 mRNA vaccines (PfizerBioNTech Comirnaty Moderna Spikevax) are the only currently authorized mRNA vaccines. There are many others in development/testing: influenza, RSV, CMV, EBV, Zika, HIV, norovirus, Hepatitis C, genital herpes, malariamany already in Phase 13 clinical trials Bacterial targets: A novel candidate vaccine against Yersinia pestis (plague) recently showed 100% efficacy in mice; human trials still pending.How many mRNA vaccines are approved? COVID‑19: PfizerBioNTech Comirnaty Moderna Spikevax These are the only licensed mRNA vaccines worldwide to date No mRNA vaccines have yet received approval for other diseases; many are in varying stages of clinical trials. mRNA vaccines in cancer: current landscape Oncology research in mRNA vaccines is rapidly advancing: Clinical trial status: Over 120 clinical trials are exploring mRNA vaccines for lung, breast, prostate, melanoma, pancreatic, brain cancers and more. Safety tolerability: Multiple trials have found mRNA cancer vaccines to be well tolerated with manageable side-effects, sometimes less than traditional chemotherapy. Promising efficacy signals: A Phase I personalized neoantigen mRNA vaccine for pancreatic cancer (16 patients) generated specific T-cell responses; responders remained recurrence-free for up to 18 months. Personalized vaccine platforms (e.g., Autogene cevumeran) are entering Phase II trials Moderna/Mercks mRNA‑4157/V940 combined with pembrolizumab showed a 44% reduction in melanoma recurrence in Phase II, now progressing into Phase III. "Universal" vaccine approach: Preclinical studies in mice (University of Florida) indicate a general mRNA booster that primes the immune system when used with checkpoint inhibitors, though human trials are still in planning. This particular vaccine could work against multiple different type of cancers and not be dependent on cancer specific antigens. Looking Ahea Challenges:The field of mRNA vaccines is relatively new. The vaccines against Covid received emergency use approval. Long term safety data is necessary. However, the concept underlying the mRNA vaccines is very promising. However, scientific research has to complete all phases of testing and show evidence of benefit with acceptable toxicity profile. Regulatory issues, cost of therapy, scaling personalized vaccine production, delivery methods, etc are issues to be handled. Hopeful future: If ongoing trials confirm efficacy, mRNA vaccines could become vital in adjuvant cancer therapy to prevent recurrence and possibly treat ongoing cancers. Conclusions mRNA vaccines work by instructing cells to produce antigens that drive immune responseoffering rapid, flexible platforms. Today, only COVID‑19 mRNA vaccines are licensed. mRNA tech is in active trials for infectious diseases and is showing very encouraging progress in oncology, with multiple phase II/III human trials underway. Several cancer-specific mRNA vaccines have successfully entered human trials, with early data indicating both safety and potential efficacy.

De-escalation of Treatment in Breast Cancer Balancing Cure and Quality of Life Breast cancer treatment has transformed dramatically over the last five decades.It used to be one-size-fits-all approach. It was dominated by radical mastectomy/modified radical mastectomy in nearly all patients and chemotherapy and radiotherapy in selected cases. Mammographic imaging is a game changer for screening and early diagnosis It is now a highly personalized approach with individualized decision making. At the heart of this evolution lies a powerful idea: de-escalation of treatment.De-escalation means deliberately reducing the intensity or extent of surgery, chemotherapy, or radiotherapy without compromising cure. The aim is not only to save lives but also to preserve quality of life, minimize side effects, and avoid long-term harm.This represents a shift from maximum tolerated treatment to minimum effective treatment. There are multiple approaches or modalities used in breast cancer treatment today. Why De-escalation MattersSurvival rates have improved with earlier detection and better systemic therapies. But aggressive treatments often leave lasting scars: Chronic lymphedema after axillary dissection Disfigurement and trauma after mastectomy Infertility and menopause from chemotherapy Cardiotoxicity, fatigue, and secondary cancers after radiotherapy These burdens have led oncologists worldwide to ask: Can we treat less and still cure? Increasingly, the answer is yeswhen patients are carefully selected. Areas of De-escalation 1. Surgery Breast Surgery Breast Conservation after NAST: In large operable and selected locally advanced cancers, neoadjuvant systemic therapy (NAST) often shrinks tumours, making breast conservation surgery (BCS) possible. With proper imaging, margin control, and radiotherapy, outcomes are comparable to mastectomy, with superior cosmetic and psychological benefits. Omission of Surgery: Trials are exploring whether patients achieving complete response after NAST can safely avoid surgery. While promising, this approach requires rigorous imaging, biopsy confirmation, and close follow-up in clinical trial settings before wider adoption. Axillary Surgery Sentinel Lymph Node Biopsy (SLNB): SLNB has replaced axillary lymph node dissection (ALND) in node-negative patients, reducing lymphedema while providing accurate staging. Recurrence rates remain equivalent to ALND. Avoiding ALND in Limited Nodal Disease: Trials such as ACOSOG Z0011, IBCSG 23-01, AMAROS, SENOMAC, and SENODAR show that patients with minimal nodal disease on SLNB can avoid ALND, sometimes substituting axillary radiation. Omission of Axillary Surgery Altogether: The SOUND trial demonstrated that early breast cancer patients with negative axillary ultrasound can avoid even SLNB without compromising safety. This major advance reduces morbidity, shoulder dysfunction, and preserves body image. 2. Radiotherapy Hypo-fractionated Schedules: Delivering higher doses in fewer sessions is now standard, offering equal efficacy, lower toxicity, and more convenience. Partial Breast Irradiation: In very low-risk patients undergoing BCS, targeting only the tumour bed instead of the entire breast achieves safe outcomes. Omission of Radiotherapy: In carefully chosen elderly, low-risk patients, omission does not compromise survival and spares them from toxicity. 3. Systemic Therapy Genomic Assays: Tests like Oncotype DX and MammaPrint help identify hormone-receptor positive patients who can avoid chemotherapy, receiving only endocrine therapy. Shorter Chemotherapy Courses: Selected regimens with reduced cycles show comparable results, minimizing cumulative toxicity. Targeted Therapy: For HER2-positive disease, studies suggest that shorter durations of trastuzumab may suffice, lowering cardiotoxicity risk. Various approaches are combined based on finding the disease biology through molecular testing 4. Endocrine TherapyEndocrine therapy improves survival but prolonged use causes menopausal symptoms, bone loss, and adherence problems. Evidence indicates that in some low-risk patients, five years of therapy may be adequate compared to ten years.Risks of De-escalationDe-escalation carries challenges that must be weighed carefully: Undertreatment: Lower-intensity therapy may increase recurrence in some patients. Tumour Heterogeneity: Low-risk appearance does not always equal indolent biology Compensatory Overtreatment: Less surgery is often offset by more systemic therapy or radiation, shifting rather than reducing toxicity. Psychological Concerns: Some patients equate less treatment with less cure, creating anxiety. Limited Long-Term Data: Many de-escalation trials have short follow-ups; survival data over decades are awaited.Thus, de-escalation must be evidence-driven, guided by tumour boards, and aligned with patient preferences. Benefits of De-escalationDespite the risks, the advantages are substantial: Reduced Toxicity: Lower rates of lymphedema, cardiotoxicity, infertility, and secondary malignancies. Improved Quality of Life: Better cosmetic outcomes, body image, and emotional recovery. Cost Savings: Particularly valuable in low-resource settings like India. Faster Recovery: Enables earlier return to family, work, and normal life. Patient-Centred Care: Aligns treatment with individual biology and personal values. Long-Term Advantages Personalized Medicine: Molecular profiling and AI tools will refine risk stratification, allowing precise tailoring of therapy intensity. Healthcare Sustainability: Avoiding overtreatment conserves resources, improving access to effective care. Survivorship Focus: With rising survival rates, quality of life and long-term well-being take centre stage. De-escalation prevents chronic complications, ensuring survivors thrive beyond cancer. Global Relevance: In resource-limited countries, evidence-based de-escalation provides safe, affordable care without compromising outcomes. The Way ForwardDe-escalation is not a universal formula. Success requires: Careful patient selection using clinical, pathological, and molecular tools Multidisciplinary tumour board decision-making Shared decision-making, incorporating patient preferences Robust clinical trial participation and long-term data generation Ultimately, de-escalation reflects the art of modern oncology: treating smarter, not harder. ConclusionBreast cancer care has entered an era of precision and compassion. De-escalationacross surgery, radiotherapy, and systemic therapybrings together the twin goals of cure and quality of life.For patients, it means fewer scars and a fuller life. For oncologists, it represents evidence-based, humane medicine. For society, it ensures sustainable, affordable cancer care.The challenge now is to refine our tools and judgment so that every woman receives not just the best chance of survival, but the best chance of living well.Andromeda Cancer Hospital now offers world class cancer treatment to patients of Haryana, Delhi and Northern India. For breast cancer management, it has a specialized centre of excellence "Andromeda Breast Cancer Centre".Andromeda Cancer Hospital Youtube Channel: http://www.youtube.com/@andromedacancerhospitalYou will find a treasure trove of informational videos at this channel. Visit this page and find out for yourself. Also request you to follow and share the link to the youtube channel.